TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27927030

Group type: EXPERIMENTAL
Intervention: Balance specific rehabilitation, 20 treatment sessions
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group treatments to reduce limitations at activity and body function level, 20 treatment sessions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Follow up for fallers
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Follow up for responders at BBS
Number of subjects: 119
Study: 25873634

Group type: EXPERIMENTAL
Intervention: ETN 50 mg QW + MTX
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: ETN 25 mg QW + MTX
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo QW + MTX
Number of subjects: 91
Study: 26058036

Group type: EXPERIMENTAL
Intervention: 0.4 ng/kg body weight LPS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 22752489

Group type: EXPERIMENTAL
Intervention: Donepezil (2.5 mg daily for initial 4 weeks followed by 5 mg daily for next 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21094804

Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Alemtuzumab
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 38
Study: 18236373

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 19
Study: 16837434

Group type: EXPERIMENTAL
Intervention: Structured triglyceride (ST)
Number of subjects: 236
Study: 14617717

Group type: EXPERIMENTAL
Intervention: Blocked practice combined with active neuromuscular stimulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Random practice along with active stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: No active stimulation assistance (control group)
Number of subjects: 34
Study: 10651692

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen bath-PUVA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Narrow-band UVB phototherapy
Number of subjects: 12
Study: 8673350

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride) plus social support by volunteers (SSV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment (alprazolam + sulpiride) plus structured psychotherapy (autogenous training)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Integrated strategy combining psychopharmacology and psychosocial interventions (SSV with or without structured psychotherapy)
Number of subjects: 72
Study: 1733156

Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 26
Study: 6376144

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (3 X 2 inhalations)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (3 X 2 inhalations)
Number of subjects: 16
Study: 31854843

Group type: COMPARATOR
Intervention: Warming (WA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warming and Straw Application (WS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean plots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Winter wheat plots
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean growing season
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α diversity indices
Number of subjects: 0
Study: 28847527

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered simultaneously with modulated electrohyperthermia (mEHT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered after modulated electrohyperthermia (mEHT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) administered before modulated electrohyperthermia (mEHT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Solely intravenous ascorbic acid (IVAA)
Number of subjects: 15
Study: 26363163

Group type: EXPERIMENTAL
Intervention: Olfactory training (TR group) - twice daily exposure to 4 odours (rose, eucalyptus, lemon, clove) for approximately 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No olfactory training (noTR group)
Number of subjects: 0
Study: 23394837

Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy (WEC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional air colonoscopy (AC)
Number of subjects: 110
Study: 21176784

Group type: EXPERIMENTAL
Intervention: 400 mg modafinil + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg THC + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400 mg modafinil + 15 mg THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 12
Study: 19237404

Group type: EXPERIMENTAL
Intervention: Controlled non-heart beating donation (CNHBD) kidneys
Number of subjects: 79

Group type: COMPARATOR
Intervention: Heart beating donation (HBD) kidneys
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: CNHBD kidneys
Number of subjects: 79

Group type: COMPARATOR
Intervention: HBD kidneys
Number of subjects: 79
Study: 17966746

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 54

Group type: COMPARATOR
Intervention: CT
Number of subjects: 54

Group type: COMPARATOR
Intervention: Non-concordance cases
Number of subjects: 54
Study: 15545308

Group type: EXPERIMENTAL
Intervention: M100240 50 mg with a high-fat meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: M100240 50 mg under fasted conditions
Number of subjects: 30
Study: 12399343

Group type: EXPERIMENTAL
Intervention: Ongoing intervention (active treatment with care management by practice nurses over 24 months)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ongoing intervention
Number of subjects: 211
Study: 9806290

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study: 7796302

Group type: EXPERIMENTAL
Intervention: Imagery mediation instructions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bizarre imagery instructions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Image mediator for every face-name pair
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Presence of original mediator during 1-week recall
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Instructions to form image mediators
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased focus during encoding
Number of subjects: 24
Study: 1972648

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice a day for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 514499

Group type: EXPERIMENTAL
Intervention: Amipaque 280 mg I/ml
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conray meglumine 282 mg I/ml
Number of subjects: 21
Study: 6414060

Group type: EXPERIMENTAL
Intervention: Estrogen (E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2 + P
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated ovariectomized women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menstruating women in follicular phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups studied (including untreated)
Number of subjects: 0
Study: 30869798

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0
Study: 29941708

Group type: EXPERIMENTAL
Intervention: Qi‐Zhi‐Wei‐Tong granules
Number of subjects: 197
Study: 26809275

Group type: EXPERIMENTAL
Intervention: Higher serum 25(OH)D (Q5)
Number of subjects: 1000
Study: 24641604

Group type: EXPERIMENTAL
Intervention: Combined subcision and cryoroller
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined subcision and dermaroller
Number of subjects: 30
Study: 22037718

Group type: EXPERIMENTAL
Intervention: Septoplasty with measured bleeding
Number of subjects: 71
Study: 20200548

Group type: EXPERIMENTAL
Intervention: Device-guided slow-breathing (DGB) exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 40
Study: 19065434

Group type: EXPERIMENTAL
Intervention: Spectacle use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaires and focus group discussions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to spectacle use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prescribing practices of local opticians
Number of subjects: 0
Study: 15561050

Group type: EXPERIMENTAL
Intervention: Closed perfusion system with heparin coating and centrifugal pump
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional system with uncoated circuit, roller pump, and hard-shell venous reservoir
Number of subjects: 41
Study: 11376665

Group type: EXPERIMENTAL
Intervention: Nitroglycerin in the form of transdermal therapeutic system releasing 5 mg of nitroglycerin in 24 h
Number of subjects: 30
Study: 9259112

Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid (ASA) per day
Number of subjects: 466

Group type: COMPARATOR
Intervention: nicametate citrate (a vasodilator)
Number of subjects: 466
Study: 8029782

Group type: EXPERIMENTAL
Intervention: Loderix (setastinum)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hismanal (astemizole)
Number of subjects: 21
Study: 3125269

Group type: EXPERIMENTAL
Intervention: 1000 mg diflunisal 2 h preoperatively and then 500 mg twice daily for 2.5 days
Number of subjects: 169

Group type: COMPARATOR
Intervention: Veralgin (1 tablet twice daily beginning 2 h prior to operation)
Number of subjects: 169
Study: 28844518

Group type: EXPERIMENTAL
Intervention: Hydration plus one-sixth molar sodium bicarbonate
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no hydration)
Number of subjects: 93
Study: 27184779

Group type: EXPERIMENTAL
Intervention: C1 INH (20,000 units every other day for 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (administered every other day for 2 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: C1 INH (measured before and after plasmapheresis)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (measured before and after plasmapheresis)
Number of subjects: 18
Study: 24412649

Group type: EXPERIMENTAL
Intervention: Dopamine precursor depletion (tyrosine and phenylalanine deficient drink)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid mixture (control)
Number of subjects: 13
Study: 22851734

Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g/d for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: White chocolate (flavanol-free)
Number of subjects: 12
Study: 19034538

Group type: EXPERIMENTAL
Intervention: Gaseous ozone (HealOzone) applied for 30 seconds
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% chlorhexidine gel (Corsodyl) applied for 30 seconds
Number of subjects: 40
Study: 17687578

Group type: EXPERIMENTAL
Intervention: Interactive visuo-motor therapy system (VR-based motor neurorehabilitation)
Number of subjects: 0
Study: 15792199

Group type: EXPERIMENTAL
Intervention: Vektor-Titan stem in cementless THR
Number of subjects: 250
Study: 11680727

Group type: EXPERIMENTAL
Intervention: Bi-caval venous cannulation and crystalloid cardioplegia (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right atrial cannulation and crystalloid cardioplegia (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right atrial cannulation and blood cardioplegia (Group C)
Number of subjects: 60
Study: 9643619

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study: 8044962

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/d SC for 1 month)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study: 2854455

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg per day orally for 14 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study: 30471928

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) 800 kcal for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 20
Study: 28737409

Group type: EXPERIMENTAL
Intervention: 800 mg immediate-release tablet of ibuprofen
Number of subjects: 37
Study: 26138726

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 23897066

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise advice)
Number of subjects: 450
Study: 20626531

Group type: EXPERIMENTAL
Intervention: Itraconazole pulse regimen (200 mg b.i.d. for 1 week, off for 3 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous regimen (Itraconazole 100 mg b.i.d. continuously)
Number of subjects: 50
Study: 19414509

Group type: EXPERIMENTAL
Intervention: InVEST training
Number of subjects: 138

Group type: COMPARATOR
Intervention: NIA strength training program
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: InVEST training (post hoc analysis)
Number of subjects: 138
Study: 17710021

Group type: EXPERIMENTAL
Intervention: High-dose I-131 therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 50
Study: 15511470

Group type: EXPERIMENTAL
Intervention: Awake group (thoracic epidural anesthesia at T4-T5)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (general anesthesia with double-lumen intubation and thoracic epidural anesthesia)
Number of subjects: 60
Study: 11778950

Group type: EXPERIMENTAL
Intervention: Vitamin B1 (75 mg, once a day) for 1 month
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg, twice a day) for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 9472838

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg/day
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Venlafaxine 200 mg/day
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 8564350

Group type: EXPERIMENTAL
Intervention: Self-adhesive breast forms
Number of subjects: 67
Study: 2565119

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (Drug-free period)
Number of subjects: 10
Study: 1104060

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 500

Group type: COMPARATOR
Intervention: No heparin prophylaxis (Control)
Number of subjects: 500
Study: 31679670

Group type: EXPERIMENTAL
Intervention: Thigh tourniquet for 60 minutes followed by calf tourniquet inflation and thigh tourniquet deflation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thigh tourniquet throughout surgery
Number of subjects: 20
Study: 28213005

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 25733201

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg per day) plus Metformin (1000 mg twice per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus Metformin
Number of subjects: 25
Study: 23392759

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg two or three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21365504

Group type: EXPERIMENTAL
Intervention: Vagus nerve preservation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 20306771

Group type: EXPERIMENTAL
Intervention: Self-reported health complaints and use of medicines among females
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Retrieval of information from package insert
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Retrieval of information from parents or adult relatives
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Retrieval of information from friends or schoolmates
Number of subjects: 514
Study: 16904773

Group type: EXPERIMENTAL
Intervention: Intravenous sedation (Fentanyl and Midazolam)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Local anesthesia (1% lignocaine)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Combined local anesthesia and sedation
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Neither sedation nor local anesthesia
Number of subjects: 611

Group type: COMPARATOR
Intervention: Local anesthesia only
Number of subjects: 611

Group type: COMPARATOR
Intervention: Sedation only
Number of subjects: 611

Group type: COMPARATOR
Intervention: Combined local and sedation
Number of subjects: 611
Study: 15599193

Group type: EXPERIMENTAL
Intervention: Hearing aids + Audiological Rehabilitation (HA + AR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Hearing aids alone (Control)
Number of subjects: 106
Study: 11157562

Group type: EXPERIMENTAL
Intervention: High-density surface EMG (sEMG) technique
Number of subjects: 0
Study: 10897096

Group type: EXPERIMENTAL
Intervention: Reference formulation of racemic chlorpheniramine (8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vietnamese-tested formulation of racemic chlorpheniramine (8 mg)
Number of subjects: 12
Study: 1813860

Group type: EXPERIMENTAL
Intervention: 0.5 g vitamin C daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 6095659

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at bedtime)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402

Group type: COMPARATOR
Intervention: Cimetidine (400 mg at bedtime)
Number of subjects: 402
Study: 31886617

Group type: EXPERIMENTAL
Intervention: Improved enzyme variant (L8F/A33I/M45Y/F50A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-OT variant (L8F/M45Y/F50A)
Number of subjects: 0
Study: 29059415

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 2149

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 2149
Study: 26696290

Group type: EXPERIMENTAL
Intervention: 16-week intervention targeting home food and activity environments
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 349
Study: 24053310

Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS; Ajust(®))
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard mid-urethral sling (SMUS; TVT-O)
Number of subjects: 137
Study: 21271232

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (1 µg/kg BW/h for 10 min, then 0.2-0.4 µg/kg BW/h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 20
Study: 18941918

Group type: EXPERIMENTAL
Intervention: Intensive instruction in physical examination (n = 46)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual instruction (control group, n = 75)
Number of subjects: 121
Study: 16979847

Group type: EXPERIMENTAL
Intervention: Disulfiram 62.5 mg/day with cocaine 0.25 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day with cocaine 0.25 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Disulfiram 62.5 mg/day with cocaine 0.5 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg/day with cocaine 0.5 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocaine 0.25 mg/kg
Number of subjects: 12
Study: 15482040

Group type: EXPERIMENTAL
Intervention: Manual-based cognitive-behavioral treatment for anxiety
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Child involvement at midtreatment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Increased involvement during therapy (positive involvement shifts)
Number of subjects: 59
Study: 11497192

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension
Number of subjects: 951

Group type: COMPARATOR
Intervention: Combined hypertension
Number of subjects: 951
Study: 10342793

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day bendrofluazide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8115668

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 18
Study: 2812168

Group type: EXPERIMENTAL
Intervention: Daily machine haemofiltration (MHF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous arteriovenous haemofiltration (CAVHF)
Number of subjects: 7
Study: 1251146

Group type: EXPERIMENTAL
Intervention: Sustained-release KC1 preparation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-sustained-release KC1 coated tablet
Number of subjects: 10
Study: 30739130

Group type: EXPERIMENTAL
Intervention: Toreforant 30 mg/day (weeks 0-52)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (weeks 0-12) followed by toreforant 30 mg/day (weeks 12-52)
Number of subjects: 21
Study: 28968888

Group type: EXPERIMENTAL
Intervention: 3 different ART regimens
Number of subjects: 26
Study: 26184298

Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24359521

Group type: EXPERIMENTAL
Intervention: Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Dummy Baoji Tablets 0.9 g and Baoji Pills 3.7 g
Number of subjects: 288

Group type: COMPARATOR
Intervention: Dummy Baoji Tablets 0.9 g and dummy Baoji Pills 3.7 g
Number of subjects: 288
Study: 21170684

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with CoQ (Med+CoQ diet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med diet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA diet)
Number of subjects: 20
Study: 19095421

Group type: EXPERIMENTAL
Intervention: EQ-5D utility score
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: BPDSI-IV
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: EQ-VAS
Number of subjects: 49
Study: 16878346

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg immediate release (IR) formulation
Number of subjects: 0